American Medical Systems, Inc.'s GreenLight HPS(R) Approved for Use in Japan
As the worldwide market leader in laser BPH treatment, AMS' GreenLight provides treatment with fewer side effects than TURP, improving clinical outcomes and patient safety for individuals with mild to severe BPH symptoms. The system is designed to enable the treatment of a wide range of gland sizes, as well as for patients on anti-coagulation therapy.
"We are thrilled to offer this leading-edge technology to provide a safer and less-invasive BPH treatment for Japanese men," said Mike Ryan, AMS' vice president and general manager for Asia Pacific, Latin America and Canada. "The approval of GreenLight represents a significant opportunity in Japan, as BPH is one of the most common diseases among older Japanese men, with the number of treatment procedures growing by over 4 percent each year."
GreenLight's high performance system (HPS) delivers efficient procedure times and the ability to treat large glands. The system will be offered in Japan through an exclusive distribution agreement with MC Medical, Inc., a subsidiary of Mitsubishi Corporation and a leading supplier of minimally invasive medical devices and supplies in Japan.
"Over 500,000 patients worldwide have been treated with GreenLight and with nearly 4 million men suffering from moderate to severe BPH symptoms in Japan, this is a great opportunity for us to help a growing population," Ryan said. "Not only does this expansion strengthen AMS' global presence but it also allows us to leverage MC Medical's highly regarded reputation within the Japanese urological community and its sales organization to reach key academic and private medical centers throughout the country."
For more information about AMS' GreenLight line of laser therapy systems for the treatment of BPH, visit http://www.americanmedicalsystems.com.
About American Medical Systems:
American Medical Systems, headquartered in Minnetonka, Minnesota, is a diversified supplier of medical devices and procedures to treat incontinence, erectile dysfunction, benign prostatic hyperplasia (BPH), pelvic floor prolapse and other pelvic disorders in men and women. These disorders can significantly diminish one's quality of life and profoundly affect social relationships. In recent years, the number of people seeking treatment has increased markedly as a result of longer lives, higher-quality-of-life expectations and greater awareness of new treatment alternatives. American Medical Systems' products reduce or eliminate the incapacitating effects of these diseases, often through minimally invasive therapies. The Company's products were used to treat approximately 340,000 patients in 2010.
More information about the Company and its products can be found at its website www.AmericanMedicalSystems.com and in the Company's Annual Report on Form 10-K for 2010 and its other SEC filings.
SOURCE American Medical Systems